Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

United States IVD Market Predicted to Reach $37 Billion by 2026 Driven by a High Prevalence of Chronic Disease - ResearchAndMarkets.com


The "United States IVD Market (By Application Segment, Products, Region, End Users), Impact of COVID-19, Major Deals, Company Profiles & Recent Developments - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The United States In-Vitro Diagnostics (IVD) market is predicted to reach nearly US$ 37 Billion by 2026. In-vitro Diagnostics (IVD) serves a key role in the healthcare value chain by significantly influencing the quality of health outcomes, patient treatment, care and downstream resource requirements.

With an aging population, technological advances and the advent of point of care diagnostics, the United States IVD market is slated to show substantial growth in the future. The increase in the US in-vitro diagnostics market is majorly driven by a high prevalence of chronic diseases, such as heart diseases, cancer, asthma, and diabetes.

It is estimated that these diseases are responsible for the majority of deaths in the United States, killing more than 1.7 million US citizens annually. All of these conditions can be diagnosed and monitored using IVD products. Thus, IVDs have proved to be beneficial in managing these chronic conditions. However, some of the factors limiting the growth of the market are a lack of proper reimbursement policies and lack of skilled lab technicians.

Impact of COVID-19 on United States In-Vitro Diagnostics Market

The COVID-19 outbreak has become a global stress test. The disease has infected over 110 Million people worldwide. Globally the death toll has reached 2,432,622 according to the latest statistics from the Worldometers (as of February 17, 2021). The number is still growing, and the duration of the pandemic is still difficult to predict.

The COVID-19 outbreak has created a sense of urgency and panic among people globally. While people are being advised to stay indoors, healthcare professionals and researchers have registered a state of urgency. In this scenario, the in-vitro diagnostics forms the crux of increased testing. Manufacturers in the in-vitro diagnostic market are focusing on developing novel technologies for maximum testing within a minimum period.

The novel coronavirus has accelerated the research and development activities in the in-vitro diagnostics market. Development and production in maximum numbers is the need of the hour. Therefore, quick FDA approvals are proving to be the cherry on the cake for the growth of the in-vitro diagnostic market.

United States In-Vitro Diagnostics Market - Application Segments Analysis

United States In-Vitro Diagnostics Market - Products Analysis

United States In-Vitro Diagnostics Market - Regional Analysis

United States In-Vitro Diagnostics Market - End Users Analysis

Key Topics Covered:

1. Executive Summary

2. Impact of COVID-19 on United States In-Vitro Diagnostics Market

3. United States - In-Vitro Diagnostics Market and Forecast (2013 - 2026)

4. United States - In-Vitro Diagnostics Market Share and Forecast (2013 - 2026)

5. By Application Segments - United States In-Vitro Diagnostics Market and Forecast (2013 - 2026)

6. By Products - United States In-Vitro Diagnostics Market and Forecast (2013 - 2026)

7. By Region - United States In-Vitro Diagnostics Market and Forecast (2013 - 2026)

8. By End User - United States In-Vitro Diagnostics Market and Forecast (2013 - 2026)

9. United States In-Vitro Diagnostics Market - Company Profiles

10. United States IVD Market - Major Deals

11. United States In-Vitro Diagnostics Market - Growth Drivers

12. United States In-Vitro Diagnostics Market - Challenges

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/fo6ql4


These press releases may also interest you

19 avr 2024
Voxtur Analytics Corp. , a North American technology company creating a more transparent and accessible real estate lending ecosystem, is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market...

19 avr 2024
On April 19, 2024, the board of directors of Portland General Electric Company declared a quarterly common stock dividend of $0.50 per share, representing an increase of 5.3%, or $0.10 per share, on an annualized basis. The company's dividend is...

19 avr 2024
Adyton Resources Corporation  ("Adyton" or the "Company") announces it has closed its previously announced non-brokered private placement offering, pursuant to which it has issued 50,000,000 common shares of the Company ("Shares") at a price of...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

19 avr 2024
Lion Group Holding Ltd. ("Lion" or "the Company") , the operator of an all-in-one trading platform that offers a wide spectrum of products and services, today announced that on April 18, 2024, it received a delinquency notification letter from the...

19 avr 2024
Cosmos Health Inc. ("Cosmos Health" or the "Company'') , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor...



News published on and distributed by: